OncoMatch/Clinical Trials/NCT05413421
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Is NCT05413421 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for metastatic prostate cancer.
Treatment: ORIC-944 · Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets · Apalutamide (Erleada™) 60 mg or 240 mg tablets · Darolutamide (Nubeqa®) 300 mg tablets · Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets — The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rocky Mountain Cancer Center · Colorado Springs, Colorado
- South Florida Oncology and Hematology · Plantation, Florida
- Illinois Cancer Specialists · Arlington Heights, Illinois
- Comprehensive Urologic Care · Lake Barrington, Illinois
- First Urology · Jeffersonville, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05413421 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages